State Street Corp Acurx Pharmaceuticals, Inc. Transaction History
State Street Corp
- $2.47 Trillion
- Q4 2024
A detailed history of State Street Corp transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 43,466 shares of ACXP stock, worth $16,951. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,466
Previous 43,466
-0.0%
Holding current value
$16,951
Previous $82,000
57.32%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
31Shares Held
1.42MCall Options Held
13.6KPut Options Held
4K-
Vanguard Group Inc Valley Forge, PA529KShares$206,4460.0% of portfolio
-
Prospect Financial Services LLC Melville, NY329KShares$128,3390.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$57,1350.0% of portfolio
-
Morgan Stanley New York, NY106KShares$41,4180.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA48.4KShares$18,8650.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.51M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...